Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824552 | 0.91 | MAOA (0.36) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL27717690 | 0.85 | MAOA (0.39) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL534825 | 0.84 | MAOA (0.38) | MAOAMAOBTRPV4CYP11B2CYP11B1 | |
| SCHEMBL14039187 | 0.82 | MAOA (0.42) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL19437202 | 0.80 | MAOA (0.41) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL8236340 | 0.80 | MAOA (0.41) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL16824548 | 0.80 | MAOA (0.41) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL16824572 | 0.80 | MAOA (0.41) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL22904292 | 0.80 | MAOA (0.41) | MAOAMAOBMPOTRPV4CYP11B2 | |
| SCHEMBL16962135 | 0.80 | MAOA (0.41) | MAOAMAOBMPOTRPV4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304917-B1 | Pleuromutilin derivative containing a thiazolo[5,4-c]pyridine side chain, and a preparation method and application thereof | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-05-20 | — | — | US | claimed |
| US-12275734-B1 | Pleuromutilin onium salt derivative containing a 3H-imidazo[4,5-c]pyridine side chain, and a preparation method and application thereof | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-04-15 | — | — | US | claimed |
| CN-119409595-A | Synthesis method of 2-cyano-5-fluorobenzyl bromide | 西安宇特邦医药科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118546155-A | Pleuromutilin derivative containing thiazolo [5,4-C ] pyridine side chain and preparation method and application thereof | 西安康诺化工有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118546138-A | 3H-imidazo [4,5-C ] pyridine pleuromutilin onium salt derivatives, and preparation method and application thereof | 西安康诺化工有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118184571-A | Synthesis method of trelagliptin succinate impurity compound | 浙江燎原药业有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117700368-A | Synthesis method of pentanitrogen guanidine salt chiral phase transfer catalyst | 四川大学 | 2024-03-15 | — | — | CN | claimed |
| CN-112939937-B | Synthesis process of trelagliptin succinate | 合肥工业大学 | 2023-09-22 | — | — | CN | claimed |
| CN-114105889-B | Preparation method and application of key intermediate of DPP-IV inhibitor | 山东创新药物研发有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-116143748-A | Preparation method of trelagliptin succinate related substances | 浙江燎原药业有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-112552281-A | Synthetic process of trelagliptin succinate bulk drug | 石家庄市华新药业有限责任公司 | 2021-03-26 | — | — | CN | claimed |
| CN-108794448-B | Preparation method of trelagliptin and salt thereof | 四川科伦药物研究院有限公司 | 2021-01-26 | — | — | CN | claimed |
| CN-111458423-A | Method for analyzing and determining 2-cyano-5-fluorobenzyl bromide in trelagliptin succinate | 浙江华贝药业有限责任公司 | 2020-07-28 | — | — | CN | claimed |
| CN-110698432-A | Benzyl piperazine compound, preparation method thereof and application thereof in antivirus | 中国医学科学院医药生物技术研究所 | 2020-01-17 | — | — | CN | claimed |
| CN-110590708-A | Aroyl piperazine compound, preparation method thereof and application thereof in antivirus | 中国医学科学院医药生物技术研究所 | 2019-12-20 | — | — | CN | claimed |
| CN-109331019-A | A kind of preparation method of compound amber love song Ge Lieting tablet | 深圳前海九华国际供应链管理有限公司 | 2019-02-15 | — | — | CN | claimed |
| CN-105968093-B | The preparation method of amber love song Ge Lieting | 郑州明泽医药科技有限公司 | 2018-09-28 | — | — | CN | claimed |
| CN-107337664-A | One koji Ge Lieting preparation method | 上海现代制药股份有限公司 | 2017-11-10 | — | — | CN | claimed |
| EP-3083580-A1 | A PROCESS FOR PREPARATION OF TRELAGLIPTIN SUCCINATE | Harman Finochem Limited (IN) | 2016-10-26 | — | — | EP | claimed |
| WO-2015092805-A1 | A PROCESS FOR PREPARATION OF TRELAGLIPTIN SUCCINATE | HARMAN FINOCHEM LIMITED (IN) | 2015-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275734-B1 | Pleuromutilin onium salt derivative containing a 3H-imidazo[4,5-c]pyridine side chain, and a preparation method and application thereof | PLEC, PML, MRPL21 | MAOA 3653/4885MAOB 3718/4885MPO 2739/4885 |
| US-12304917-B1 | Pleuromutilin derivative containing a thiazolo[5,4-c]pyridine side chain, and a preparation method and application thereof | PLEC, MLN, MRPL21 | MAOA 2866/4885MAOB 2330/4885MPO 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.